MedTrace Logo

Eyenovia MiDD Usability Study

NCT03480906 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-07-26

No results posted yet for this study

Summary

This study is to evaluate the usability and patient tolerability for microtherapeutic dosing of commercially available ocular medication via the Eyenovia microdose delivery system (MiDD)

Conditions

  • Intraocular Pressure

Interventions

DRUG

Latanoprost

Latanoprost ophthalmic solution administered as a microdose spray

DRUG

Latanoprost

Latanoprost ophthalmic solution administered as an eyedrop

Sponsors & Collaborators

  • Eyenovia Inc.

    lead INDUSTRY

Principal Investigators

  • Reuben Orillac, MD · Clinica de Ojos Orillac-Calvo

  • Ernesto Calvo, MD · Clinica de Ojos Orillac-Calvo

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-12
Primary Completion
2018-03-17
Completion
2018-03-17

Countries

  • Panama

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03480906 on ClinicalTrials.gov